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A
wide range of chromosomal rearrangements have
been identified in human cancers especially in
leukemia.1,2 Murine models that recapitulate chro-
mosomal translocations are essential for understand-
ing the determinants of malignancies and as a basis for preclinical
development of rational therapeutic methods. Genetically
engineered murine models involving chromosomal translocation
genes have been generated using transgenic approaches or gene
knockin.3,4 However, the closest model is the creation of bona
fide chromosomal translocations, which recapitulate the physio-
logic levels of the fusion genes, the reduced dosage of the wild-
type alleles and the contribution of the reciprocal products of the
translocations. This has been achieved in vivo using the Cre-loxP
system in embryonal stem cells,5which is labor intensive and time
consuming. The CRISPR/Cas9 system is a versatile tool for
genomic engineering. Transduction of target cells with vectors
encoding Cas9 and sgRNAs targeting two genomic loci causes
two DNA double strand breaks (DSBs), which could induce
chromosomal rearrangements as a result from non-homologous
end joining-based DNA repair.6 This strategy has been used to
model oncogenic chromosomal rearrangements in murine7–10 or
human11 cells in vivo. However, given the challenges of delivering
CRISPR/Cas9 vectors into hematopoietic cells, the penetrance of
leukemogenesis has been shown with low frequency in vivo.11
Here we establish an efficient methodology to generate
chromosomal translocations in mice hematopoietic cells based
on a vector design enabling convenient lentiviral delivery of
multiple sgRNAs to hematopoietic cells from a Cas9 expressing
mouse strain.
TheKMT2A(MLL)gene constitutes ahotspot for chromosomal
translocations in human leukemia, resulting in over 135 different
leukemia-associated KMT2A gene fusions.2KMT2A-MLLT1
defines a leukemia subtype with poor outcome. This translocation
frequently constitutes the sole genomic lesion to drive the
leukemia,12 providing a good model to establish this approach.
We designed a strategy to induce Kmt2a-Mllt1 translocations in
murine hematopoietic cells using the CRISPR/Cas9 system
followed by transplantation into lethally irradiated recipient mice
(Fig. 1A-B). Given the large size of Cas9, it is challenging to
transducemurine hematopoietic cellswith lentiviral vectors coding
Cas9 together with sgRNAs. We therefore took advantage of the
Cas9 knockin mouse,13 in which the Cas9 and a GFP reporter are
expressed constitutively in thewhole body. Using a single lentiviral
vector to deliver two U6 promoter-sgRNA cassettes is an efficient
way to induce two DSBs simultaneously.14 We constructed a
lentiviral vector coding sgRNA and a fluorescent marker
(sg_shuttle_RFP657, Supplementary Fig. 1A, http://links.lww.
com/HS/A96) with special designs: (1) The small size of the
backbonewithminimuminterval sequencesbetween eachmodules
improves the virus titer; (2) The isocaudomer sites flanking the
sgRNA cassettes facilitates the combination of multiple single
sgRNAs from individual vector into one vector (Supplementary
Fig. 1B, http://links.lww.com/HS/A96). We firstly cloned several
individual sgRNAs targeting the equivalent introns of Kmt2a and
Mllt1 that are orthologue regions in the human leukemia
translocation (Fig. 1A-B). The editing efficiency of each sgRNA
was firstly validated in NIH 3T3 cells stably expressing Cas9
(Supplementary Fig. 1C, http://links.lww.com/HS/A96), then the
most efficient sgRNAs targeting Kmt2a and Mllt1 loci were
combined into one vector (sg_ K-M). Transduction of this vector
coding two sgRNAs in NIH 3T3 cells generated the Kmt2a-Mllt1
translocation efficiently (Supplementary Fig. 1D, http://links.lww.
com/HS/A96).
We then applied this approach to target primary murine
hematopoietic cells (Fig. 1C). Since the original Cas9 knockin
mouse has a mixed background of B6/129/FVB,13 we crossbred
the Cas9 mice with the inbred C57BL/6 mice and used the F1
progenies (Cas9GFP+/) as the bone marrow donors. Given the
C57BL/6 haploidentical setting, these cells can reconstitute the
hematopoietic system in lethally irradiated C57BL/6 recipient
mice without inducing graft-versus-host disease. Transduction of
these bone marrow cells with the sgRNA vector (sg_ K-M) lead to
a detectable genomic rearrangement between the Kmt2a and
Mllt1 locus at 4 days after transduction in ex vivo cultures
(Fig. 1D). The expression of both Kmt2a-Mllt1 and the reciprocal
Mllt1-Kmt2a fusions were detected by RT-PCR and verified by
sequencing (Fig. 1D-E). Droplet Digital PCR (ddPCR) performed
on genomic DNA from unsorted cells detected a copy number
ratio of 0.003 of the Kmt2a-Mllt1 with respect to the wild type
Kmt2a, implicating that ∼0.6% of the cells harbor the
translocations (Fig. 1F). Thus this strategy is fast and practical
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to generate de novo translocations in primary murine hemato-
poietic cells.
Transplantation of the engineered cells into lethally irradiated
C57BL/6 mice lead to engraftment of a GFP+ population, which
can be detected in peripheral blood at 4 weeks after
transplantation. Three out of nine mice displayed a marked
increasing of the RFP657+ populations in the myeloid population
over time, which suggested the sgRNA-transduced population to
become dominant in vivo (Fig. 2A). By 120 days after
transplantation, 100% of the Kmt2a-Mllt1 mice presented signs
of sickness and were sacrificed (Fig. 2B). Post-mortem examina-
tion of Kmt2a-Mllt1 mice confirmed the development of
leukemia with predominant myeloblasts in the peripheral blood,
splenomegaly and extensive infiltration of leukocytes into
peripheral organs such as liver and kidneys (Fig. 2C and
Supplementary Fig. 2, http://links.lww.com/HS/A96). The immu-
nophenotype of the bone marrow cells was consistent for a
myeloid leukemia that was positive for myeloid markers (Mac-
1hi, Gr-1int) but not for lymphoid markers (CD3, B220) or
progenitor markers (Sca-1, c-Kit) (Fig. 2D).
The presence of the reciprocal translocations t(9;17) in
leukemia cells was confirmed by FISH using pan-chromosome
probes (Fig. 2E). The Kmt2a-Mllt1 gene fusion and its product
were verified by PCR and sequencing. Notably, both the non-
rearranged allele of Kmt2a and Mllt1 as well as the reciprocal
productMllt1-Kmt2a fusion were also expressed in the leukemia
cells (Fig. 2F). Transplantation of the bone marrow cells from the
primary tumor mice into lethally irradiated second recipients
manifested diseases in a shorter latency of 2–4 weeks, confirms
the self-renewal capacity and the aggressiveness of this leukemia
(Fig. 2B).
We next attempted to model the TCF3-HLF translocation
defining a highly aggressive leukemia subtype for which so far no
representative mouse model could be engineered.15 Given the
Figure 1. Induction of the Kmt2a-Mllt1 rearrangement in murine hematopoietic cells using the CRISPR/Cas9 system. (A) Schematic of the t(9;17)
involving the Kmt2a and Mllt1 loci. Introns targeted by sgRNAs are indicated. (B) Schematic of the Kmt2a and Mllt1 loci with the locations of the primers used for
genotyping. (C) Strategy for the generation of the Kmt2a-Mllt1 rearrangement in murine bone marrow cells and transplantation experiments. (D) PCR genotyping of
cultured bone marrow cells from Cas9GFP+/mice transduced with or without sgRNA vectors (sg_K-M). PCRs were performed on genomic DNA (gDNA) or cDNA
from bone marrow cells ex vivo cultured for 4 days after transduction. (E) Sequence of the PCR products from cDNA showing the Kmt2a-Mllt1 and Mllt1-Kmt2a
junctions. (F) ddPCR quantification of Kmt2a and Kmt2a-Mllt1 frequencies in gDNA from bone marrow cells ex vivo cultured for 4 days after transduction of sgRNA
vectors. Signal amplitudes of amplicon-positive (blue) and -negative (gray) droplets for the detection of Kmt2a and Kmt2a-Mllt1 (left and middle) and the copy
number ratio ofKmt2a-Mllt1with respect toKmt2a in Ctrl and sgRNA transduced groups (right, data are presented asmeanwith SD). Primer pairs for detections are
indicated in the parenthesis; NTC, no template control; Ctrl+Spike-in, control gDNA spike-in with synthetic artificial DNA templates of Kmt2a-Mllt1.
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frequent PAX5 heterozygous deletions and reduced gene
expression identified in this leukemia,16 we tested the hypothesis
if the Tcf3-Hlf translocation could induce a mouse leukemia
when established in a Pax5 haploinsufficient context (Supple-
mentary Fig. 3A–C, http://links.lww.com/HS/A96). We cross-
bred the Cas9 mice with the Pax5 heterozygous mice (Pax5+/,
C57BL/6 inbred)17 and used the F1 progenies (Cas9GFP+/
Pax5+/+ or Cas9GFP+/ Pax5+/) as the bone marrow donors.
Transduction of the bone marrow cells with validated sgRNAs
targeting the equivalent introns of mice Tcf3 and Hlf loci (sg_T-
H) lead to detectableTcf3-Hlf translocation and the expression of
the fusion product (Supplementary Fig. 3D-E, http://links.lww.
com/HS/A96). The generation of the Tcf3-Hlf translocation was
less effective than the Kmt2a-Mllt1 translocation, with ∼0.16%
of the cells detected by ddPCR to harbor the translocation
(Supplementary Fig. 3F, http://links.lww.com/HS/A96).
Figure 2. TheKmt2a-Mllt1 fusion induces acute myeloid leukemia. (A) Flow cytometry analysis of peripheral blood cells from a recipient mouse transplanted
with Cas9GFP+/ bone marrow cells transduced with sg_K-M vectors at 6 weeks (W6) and 12 weeks (W12) after transplantation. A RFP657+ population with
myeloid features is emerging over time. (B) Kaplan-Meier survival curves of mice transplanted withCas9GFP+/ bonemarrow cells transduced with sg_K-M vectors
developing primary (1st) and secondary (2nd) Kmt2a-Mllt1 leukemia. (C) May-Grünwald Giemsa staining of blood smears and Hematoxylin-Eosin staining of tissue
sections of kidneys and livers from control and Kmt2a-Mllt1 leukemia mice. (D) Fluorescence in situ hybridization (FISH) on metaphases of splenocytes from Kmt2a-
Mllt1 leukemic mice using paints for chromosome 9 (FITC) or chromosome 17 (Cy3). White arrows indicate the translocated chromosomes. (E) Flow cytometry
analysis of bone marrow cells stained with fluorescent antibodies in control and Kmt2a-Mllt1 leukemic mice. (F) RT-PCR detection of the expression of the non-
translocated alleles of Kmt2a and Mllt1, and the fusions of Kmt2a-Mllt1 and Mllt1-Kmt2a in a control and a Kmt2a-Mllt1 leukemic mouse.
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After transplantation of the engineered cells into lethally
irradiated C57BL/6 recipients, the Tcf3-Hlf translocation was
detected in genomic DNA from peripheral blood and bone
marrow at 4weeks after transplantation (Supplementary Fig. 3G-
H, http://links.lww.com/HS/A96). However, no progression to
leukemia could be detected even after a follow-up for up to 11
months. Post-mortem examination did not reveal any abnormal-
ity of spleen, kidney, liver and bone marrow cells and the Tcf3-
Hlf translocation signal was undetectable in bone marrow cells
(Supplementary Fig. 3H, http://links.lww.com/HS/A96). This
suggests a selective disadvantage of cells carrying Tcf3-Hlf in
vivo, confirming similar observations madewith a knockinmodel
of Tcf3-Hlf.18 Thus, despite the frequency of PAX5 haploinsuf-
ficiency inTCF3-HLF positive patients, deletion of Pax5 does not
counteract the negative selection pressure by Tcf3-Hlf. Notably,
the Kmt2a-Mllt1 myeloid leukemia can be established in the
Pax5+/ background with similar dynamics as in the Pax5 +/+
background confirming that a reduced Pax5 gene dosage does
not influence the leukemogenic activity of Kmt2a-Mllt1 (Supple-
mentary Fig. 4, http://links.lww.com/HS/A96).
Activation of oncogenes by fusion or juxtaposition to ectopic
regulatory elements constitutes important cancer initiating
events. Here, we established an efficient strategy using the
CRISPR/Cas9 system to generate leukemogenic chromosomal
translocations in vivo. We generated two types of translocations
in bone marrow cells with frequencies of 0.6% and 0.16%.
Although the generation of Tcf3-Hlf was not sufficient to induce
leukemia in this study the model can now be used to evaluate
different cells of origin and to screen for required cooperative
genetic events. Our approach can be employed to model any pair
of genes as long as the orientation to the centromere does not
result in dicentric chromosomes. Using the inbred Cas9 mouse
strain will further simplify this approach. Besides, our vector
design facilitates the combination of multiple sgRNAs to
introduce additional oncogenic lesions (Supplementary Fig. 1B,
http://links.lww.com/HS/A96). Thus, our strategy provides an
efficient way to generate precise translocations, enabling
functional modeling in mice and constitutes a framework to
study the role of cooperative events and the cells of origins in
leukemogenesis.
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